Dilated cardiomyopathy is defined in the packet as a cardiomyopathy characterized by dilation and contractile dysfunction of the left and right ventricles, and as a cause of congestive heart failure. It is also listed under the names congestive cardiomyopathy, primary dilated cardiomyopathy and idiopathic dilation cardiomyopathy. The packet lists three related entries as subtypes: familial dilated cardiomyopathy, viral dilated cardiomyopathy and non-familial dilated cardiomyopathy. No prevalence estimate is certified in this packet.

No phenotype list, age of onset or clinical description is certified in this packet, so specific symptoms and their frequencies are unknown here. The packet definition describes the condition as involving dilation and contractile dysfunction of the ventricles and as a cause of congestive heart failure.

According to the packet definition, the condition may be idiopathic, or it may result from a myocardial infarction, myocardial infection, or alcohol abuse. The packet lists familial, viral and non-familial forms as related entries. The packet contains no certified causative-gene claim and no certified inheritance pattern for this condition.

No diagnostic methods, diagnostic criteria or newborn-screening information are certified in this packet, so how the condition is diagnosed is not described here.

The packet lists one FDA record with active market status: Corlanor (ivabradine), approved through a new drug application reviewed by FDA's Center for Drug Evaluation and Research, with an approval date of 15 April 2015. The packet does not state the indication for that record. Among orphan drug designations listed for dilated cardiomyopathy, trimetazidine is designated, and two others, ixmyelocel-T and a p38 mitogen-activated kinase inhibitor, are marked withdrawn. An orphan designation is not an approval and does not indicate that a product is in development. Foundational therapies, multidisciplinary care and surveillance are not certified in this packet, so their content is unknown here.

Prognosis is not certified in this packet.

The packet lists numerous active clinical trials for dilated cardiomyopathy. Their interventions include drug therapy, biologic therapy, medical devices and other interventions, and the packet indicates that gene therapy trials are among them. Several listed studies are natural history observations, and several enroll participants with genetic or familial forms of the condition. Active clinical trials for this condition are listed on ClinicalTrials.gov.